NATICK, Mass. — Allurion Technologies has announced a new distribution partnership with Minogue Medical, a Canadian firm specializing in bariatric and obesity care, to bring its weight loss program to more patients across Canada.
The collaboration marks Allurion’s entry into the Canadian market and is part of its effort to promote what it describes as a “metabolically healthy” approach to weight loss—one that focuses not just on shedding pounds, but on preserving muscle and improving long-term health outcomes.
Minogue Medical, which has been operating in Canada for over 40 years, will distribute the Allurion Program and help integrate it into clinics across the country. The company is known for its network of dietitians, bariatric surgeons, and endoscopy specialists, as well as its role in introducing new medical technologies into Canadian healthcare systems.
“Minogue Medical has a strong track record of delivering advanced care through a patient-centered, multidisciplinary approach,” said Dr. Shantanu Gaur, CEO of Allurion. “This partnership supports our goal of establishing a new standard of care in obesity treatment.”
The Allurion Program includes a swallowable gastric balloon that does not require surgery or endoscopy for placement or removal, combined with digital tools and nutritional support. The company also anticipates expanded access to providers who offer GLP-1 therapies alongside its program to further improve outcomes.
Minogue Medical CEO Danny Minogue said the partnership aligns with the company’s mission to support evidence-based obesity treatment. “Allurion’s focus on clinical rigor complements our approach,” he said. “Together, we aim to redefine how weight management is delivered in Canada.”
The partnership is expected to broaden access to Allurion’s program and support healthcare providers in offering non-invasive, multidisciplinary solutions for obesity.
